Sanofi

Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

Julia Schwendner, Process Responsible Scientist, smiling in a green lab coat, hairnet and safety goggles while standing in front of industrial bioprocessing equipment at Sanofi's Frankfurt facility.

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

Press Releases


September 24, 2025
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

September 24, 2025
Press release: Availability of the Q3 2025 Aide mémoire

September 23, 2025
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Upcoming Events

23Sep

2025

2025 BofA Global Healthcare Conference

08:00 - 16:00 BST (London)

Conferences

Discover more

25Sep

2025

Baader Investment Conference

Conferences


24Oct

2025

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results

Discover more

Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing
Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

30th Consecutive Year of Dividend Increase

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00